Protein kinase C zeta inhibition to treat vascular permeability
US7585865B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2007 |
| Grant date | Sep 8, 2009 |
| Priority date | — |
| Expiry date | Jul 23, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.